One more question: If it's approved for DIC in Japan, can't we assume that it was approved based on data/trials that might be acceptable to the American medical establishment?
But given the financial state of the American health care system, I see your overall point.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.